Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 9/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608276 | 0.90 | RAB9A (0.53) | NPC1RAB9APPARGPPARDPPARA | |
| SCHEMBL3608726 | 0.86 | F11 (0.36) | F11NPC1RAB9ATRPM8 | |
| SCHEMBL3606040 | 0.82 | F11 (0.47) | F11NPC1RAB9AKLKB1PPARG | |
| SCHEMBL3612848 | 0.81 | XIAP (0.47) | F11NPC1RAB9AXIAP | |
| SCHEMBL3609162 | 0.81 | KMT2A (0.47) | NPC1RAB9AXIAP | |
| SCHEMBL3612495 | 0.81 | XIAP (0.50) | F11XIAPACE | |
| SCHEMBL3604413 | 0.81 | ALDH1A1 (0.47) | TRPM8XIAP | |
| SCHEMBL3613507 | 0.80 | XIAP (0.43) | F11PPARGPPARDPPARAXIAP | |
| SCHEMBL3609217 | 0.80 | XIAP (0.40) | F11TRPM8PPARGPPARDPPARA | |
| SCHEMBL3611346 | 0.80 | XIAP (0.40) | F11TRPM8PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | F11 4805/4885NPC1 326/4885RAB9A 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.